Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), emphasizing significant advancements in regulatory and commercialization preparation for OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma. The key inflection point is enhanced regulatory clarity, as the European Medicines Agency (EMA) initiated a rolling review of the OST-HER2 Conditional Marketing Authorization dossier, while both the EMA and Australia's Therapeutic Goods Administration (TGA) aligned on 3-year overall survival (OS) as the approvable efficacy endpoint. This alignment shifts the investment narrative from early proof-of-concept toward execution across a dense 2026 catalyst calendar.
The company has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence. Management's focus now centers on key milestones: 2.5-year OS data in mid-second quarter 2026, meetings with the U.S. Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in second quarter 2026, initiation of a Phase 3 trial in Australia in third quarter 2026, 3-year OS data in early fourth quarter 2026, and a potential EMA Conditional Marketing Authorization decision in fourth quarter 2026. These milestones are expected to determine whether OST-HER2 can complete the EMA submission and sustain accelerated-access momentum.
Stonegate notes that regulatory clarity is the core value inflection. The EMA rolling review, TGA endpoint alignment, MHRA Advanced Therapy Medicinal Product designation, and upcoming FDA/MHRA meetings shift OST-HER2 from Phase 2b validation toward an executable global approval pathway. Survival data remain the key catalyst stack, with 2.5-year and 3-year OS data critical for regulatory decisions.
Financing and potential Priority Review Voucher (PRV) optionality bridge the regulatory window. The company's $5.25 million raise, plus an expected $4.0 million in non-dilutive funding, supports 2026 catalysts. A potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million. For more details, the full announcement is available here.
About Stonegate: Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. For inquiries, contact Stonegate Capital Partners at (214) 987-4121 or via email at info@stonegateinc.com.
